

[Alprostadil \(prostaglandin E1\)](#)

Essential medicine status

Section:

[22. Medicines for reproductive health and perinatal care 22.7. Medicines administered to the neonate \[c\]](#)

ATC codes: [C01EA01](#)

EMLc

Indication

Other specified congenital anomaly of great arteries including arterial duct ICD11 code: [LA8C.Y](#)

INN

Alprostadil

Medicine type

Chemical agent

List type

Complementary

Formulations

**Parenteral > General injections > IV: 0.5 mg per mL in alcohol (EMLc)**

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Newborn (&lt; 1 month)

Therapeutic alternatives

[dinoprostone \(prostaglandin E2\)](#) (ATC codes: [G02AD02](#))

Parenteral > General injections > IV: 1 mg per mL

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Alprostadil \(prostaglandin E1\)](#)

DrugBank

[Prostaglandin e \(Alprostadil\)](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended updating the medicine descriptions for prostaglandin E1 and E2 to reflect active ingredients by international non-proprietary names (alprostadil and dinoprostone).